Suppr超能文献

SUMO2 的下调抑制肝癌细胞的增殖、迁移和侵袭。

Downregulation of SUMO2 inhibits hepatocellular carcinoma cell proliferation, migration and invasion.

机构信息

Department of Clinical Laboratory, Quanzhou First Hospital Affiliated to Fujian Medical University, China.

Department of Clinical Laboratory, The Hospital of Nanan City, China.

出版信息

FEBS Open Bio. 2021 Jun;11(6):1771-1784. doi: 10.1002/2211-5463.13173. Epub 2021 May 14.

Abstract

This study aimed to evaluate the prognostic value and biological function of small ubiquitin-like modifier 2 (SUMO2) in hepatocellular carcinoma (HCC). SUMO2 expression in HCC tissues was markedly higher than that in normal liver tissues, and patients with high SUMO2 expression had significantly shorter median overall survival than those with low SUMO2 expression. Furthermore, SUMO2 expression was closely correlated with lymph node metastasis and vascular invasion and was a predictor of poor prognosis. The knockdown of SUMO2 in two HCC cell lines (SMMC-7721 and Bel-7404) dramatically suppressed their proliferation, migration and invasion. Western blot analysis showed that the downregulation of SUMO2 significantly reduced the expression of Ki-67, matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) in SMMC-7721 and Bel-7404 cells. Similarly, quantitative reverse transcription-PCR revealed consistently decreased expression of MMP-9 and VEGF. Our data suggest that SUMO2 promotes proliferation, migration and invasion of HCC cells via mechanisms involving MMP-9 and VEGF. Therefore, SUMO2 may be a prognostic factor and a promising therapeutic target for patients with HCC.

摘要

本研究旨在评估小泛素样修饰物 2(SUMO2)在肝细胞癌(HCC)中的预后价值和生物学功能。SUMO2 在 HCC 组织中的表达明显高于正常肝组织,高 SUMO2 表达的患者中位总生存期明显短于低 SUMO2 表达的患者。此外,SUMO2 表达与淋巴结转移和血管侵犯密切相关,是预后不良的预测因子。在两种 HCC 细胞系(SMMC-7721 和 Bel-7404)中敲低 SUMO2 显著抑制了它们的增殖、迁移和侵袭。Western blot 分析显示,SUMO2 的下调显著降低了 SMMC-7721 和 Bel-7404 细胞中 Ki-67、基质金属蛋白酶-9(MMP-9)和血管内皮生长因子(VEGF)的表达。同样,定量逆转录-PCR 显示 MMP-9 和 VEGF 的表达持续下降。我们的数据表明,SUMO2 通过涉及 MMP-9 和 VEGF 的机制促进 HCC 细胞的增殖、迁移和侵袭。因此,SUMO2 可能是 HCC 患者的预后因素和有前途的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0be6/8167860/1825b6103961/FEB4-11-1771-g005.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验